Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development Post author: Post published:June 17, 2024 Post category:uncategorized Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays. You Might Also Like Scientists uncover brain mechanisms for social memory recall in mice February 21, 2024 Teva UK and Closed Loop Medicine announce strategic partnership to advance development of personalised medicines March 26, 2024 Study shows weather factors affect Salmonella transmission January 29, 2025
Teva UK and Closed Loop Medicine announce strategic partnership to advance development of personalised medicines March 26, 2024